A trial looking at pembrolizumab with or without sacituzumab govitecan for non small cell lung cancer that has spread (KEYNOTE D46/EVOKE-03)

This trial is looking at a targeted cancer drug called sacituzumab govitecan in combination with the immunotherapy drug pembrolizumab. The trial team are comparing this treatment to pembrolizumab alone.

You pronounce sacituzumab govitecan as sass-ih-too-zo-mab go-vih-tee-kan.

It is for people with non small cell lung cancer and:

• the cancer has spread from where it started to other parts of the body (advanced cancer)

• more than half (more than 50%) of the lung cancer cells have a protein called PD-L1 on their surface

• they have not had treatment for their advanced lung cancer before